OTCMKTS:DCHPF Dechra Pharmaceuticals (DCHPF) Stock Price, News & Analysis $46.90 0.00 (0.00%) As of 01/18/2024 Add Compare Share Share Stock Analysis Stock Analysis About Dechra Pharmaceuticals Stock (OTCMKTS:DCHPF) Get Dechra Pharmaceuticals alerts:Sign Up Key Stats Today's Range$46.90▼$46.9050-Day Range$46.90▼$46.9052-Week Range$30.00▼$47.40VolumeN/AAverage Volume1,687 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Dechra Pharmaceuticals plc is a specialty veterinary pharmaceutical company headquartered in the United Kingdom. The company develops, manufactures and markets medicines and related products for veterinary surgeons, supporting the treatment of companion animals, horses and food-producing animals. Its product portfolio covers therapeutic areas including endocrinology, dermatology, anesthesia and analgesia, cardiology, gastroenterology, infectious diseases and critical care. Dechra also provides veterinary diets and other specialized products intended to help manage animal health conditions. Founded in 1997, Dechra expanded through product development, acquisitions and international commercialization. Its operations and products serve veterinary markets across Europe, North America and other regions worldwide. In 2023, Dechra was acquired by EQT and subsequently delisted from the London Stock Exchange, becoming a privately held company.AI Generated. May Contain Errors. Read More Receive DCHPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dechra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DCHPF Stock News HeadlinesDechra Pharmaceuticals PLC (LON:DPH) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?May 13, 2022 | finance.yahoo.comFTSE 100 firms hit boardroom diversity targets but fail at executive levelMarch 16, 2022 | uk.finance.yahoo.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.October 12 at 1:00 AM | Behind the Markets (Ad)Anivive Licenses Novel Canine Cancer Therapeutic to Expand Sales and Accelerate PipelineJanuary 12, 2022 | prnewswire.comDechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At UK£0.29September 14, 2021 | finance.yahoo.comGoldman Sachs picks London for private-equity IPO as FTSE climbs after U.S. jobs dataSeptember 6, 2021 | finance.yahoo.comCalculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)August 7, 2021 | finance.yahoo.comSee More Headlines DCHPF Stock Analysis - Frequently Asked Questions How have DCHPF shares performed this year? Dechra Pharmaceuticals' stock was trading at $46.90 at the start of the year. Since then, DCHPF shares have increased by 0.0% and is now trading at $46.90. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:DCHPF CIKN/A Webdechra.com Phone441606814730FaxN/AEmployees2,457Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:DCHPF) was last updated on 1/18/2024 by MarketBeat.com Staff. From Our PartnersHOST Just Entered the AI Data Center Race in a BIG WayHost Digital Inc. (NYSE American: HOST) completed its merger with Healthy Choice Wellness Corp. on September 1...Trading Wire | SponsoredThe AI Infrastructure Play Kevin O'Leary Is BackingKevin O'Leary became a strategic investor in a NASDAQ-listed AI infrastructure company, calling it essentially...The Tomorrow Investor | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredPalantir and Wall Street are in on it…Palantir just signed a major AI deal with a company most investors have never heard of. Wall Street has pou...Monument Traders Alliance | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredFox News: Wall Street Can Seize Your RetirementFox News reported that under current law, legal title to most stocks and bonds sits with a central institution...Monetary Gold | SponsoredUrgent Attention to Executive Order #14363 (Buy This Stock Before Oct. 20thMarc Chaikin, a 60-year Wall Street veteran whose past clients include George Soros and Steve Cohen, built a s...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dechra Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Dechra Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.